Compositions and methods for treatment of multiple sclerosis
Disclosed are novel compositions and methods for the treatment of Multiple Sclerosis (MS), and in particular immunostimulatory compositions comprising muramyl dipeptide microparticles for use, e.g., in the treatment of MS.
1. A method of treating multiple sclerosis comprising administering to a subject requiring such treatment a composition comprising muramyl dipeptide cross-linked into a microparticle.
2. A method of treating symptoms of multiple sclerosis comprising administering to a subject requiring such treatment a composition comprising muramyl dipeptide cross-linked into a microparticle.
3. A method according to claim 1 , further comprising administering one or more other active agents effective in the treatment of multiple sclerosis.
4. A method according to any one of claims 1 to 3 , wherein the type of multiple sclerosis to be treated is selected from progressive and relapsing-remitting multiple sclerosis.
5. A method according claim 4 , wherein the progressive multiple sclerosis is selected from primary progressive, secondary progressive or chronic progressive multiple sclerosis.
6. A method according to claim 4 , wherein the type of multiple sclerosis to be treated is relapsing-remitting multiple sclerosis.
7. A method according to any one of claims 1 to 3 , wherein the composition is administered by means selected from intramuscular, intraperitoneal, intravenous, subcutaneous, rectal, nasal, oral, intragastric and pulmonary.
8. A method according to any one of claims 1 to 3 , wherein the composition is administered by infusion or injection.
9. A method according to any one of claims 1 to 3 , wherein the composition is administered in dose range of from 50 μg to 1500 μg.
10. A method according to any one of claims 1 to 3 , wherein the composition is administered daily, weekly, fortnightly or monthly.
11. A method according to claim 3 , wherein the one or more other active agents used in the treatment of multiple sclerosis is administered concurrently or sequentially, in any order, with the composition comprising muramyl dipeptide cross-linked into a microparticle.
12. A method according to claim 11 , wherein the one or more other active agents used in the treatment of multiple sclerosis is selected from corticosteroids, interferons, glatiramer acetate, mitoxantrone, antibodies, or combinations thereof.